Skip to main content

Swissmedic Approval for HEMGENIX®

Swissmedic Authorises CSL’s HEMGENIX® as First Gene Therapy for Hemophilia B


Bern, Switzerland – 15 January 2024 – Global biotechnology leader CSL (ASX: CSL) announced today that Swissmedic has authorised HEMGENIX® (etranacogene dezaparvovec), the first and currently only gene therapy for the treatment of male adults aged >18 years with severe or moderately severe hemophilia B (congenital Factor IX deficiency). HEMGENIX® is a one-time, single-dose treatment option that allows people living with hemophilia B to produce their own factor IX, which can lower the risk of bleeding.

The approval is based on results from the ongoing Phase III HOPE-B trial, the largest gene therapy trial in hemophilia B to date. Data from the pivotal trial show that HEMGENIX® reduces the rate of annual bleeding by delivering a functional gene that acts as a blueprint for the production of coagulation factor IX in the liver, a protein that is essential for blood clotting.
“This approval is further demonstration of CSL’s promise to pursue, develop and deliver new innovative treatment options that meet the needs of the rare disease community,” said Emmanuelle Lecomte-Brisset, Senior Vice President and Head of Global Regulatory Affairs, CSL. “We believe HEMGENIX® has the potential to change the treatment paradigm for people living with hemophilia B and the healthcare professionals who treat them, as it addresses the cause of the condition.”
“The approval of HEMGENIX® in Switzerland marks an important milestone for patients, and we look forward to collaborating with the hemophilia B community to provide access to this innovative treatment option,” said Dr. Isabelle Dahinden, General Manager Switzerland, CSL Behring. “We are proud to add this treatment to our portfolio of coagulation therapies and look forward to patients benefiting from this therapy.”

HEMGENIX® has also been approved by the U.S. Food and Drug Administration and authorised by Health Canada, and was granted conditional marketing authorization by the European Commission (EC) for the European Union and European Economic Area, and the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA). The multi-year clinical development of HEMGENIX® was led by uniQure (Nasdaq: QURE) and sponsorship of the clinical trials transitioned to CSL after it licensed global rights to commercialize the treatment.

About Hemophilia B
Hemophilia B is a life-threatening rare disease caused by a mutation on the F9 gene, resulting in low levels of functional clotting factor IX. People with the condition are particularly vulnerable to bleeds in their joints, muscles, and internal organs, leading to pain, swelling, and
joint damage. Current treatments for moderate to severe hemophilia B include life-long prophylactic infusions of factor IX to temporarily replace or supplement low levels of the blood-clotting factor.

HEMGENIX® is a gene therapy that reduces the rate of abnormal bleeding in eligible people with hemophilia B by enabling the body to continuously produce factor IX, the deficient protein in hemophilia B. It uses AAV5, a non-infectious viral vector, called an adeno-associated virus (AAV). The AAV5 vector carries the naturally occurring Padua gene variant of Factor IX (FIX-Padua) to the target cells in the liver, generating factor IX proteins that are 5x-8x more active than normal. These genetic instructions remain in the target cells, but generally do not become a part of a person’s own DNA. Once delivered, the new genetic instructions allow the cellular machinery to produce stable levels of factor IX.
The medical innovations in hemophilia B to date have significantly improved patients' lives and treatment standards. However, there is still an unmet medical need: even with lifelong prophylactic treatment, recurrent bleeding into the joints, for example, can occur. These can damage the joint, lead to deformities and pain and, in the event of a cerebral hemorrhage, can be fatal. In addition, the fear of bleeding continues to cause ongoing psychosocial stress and physical limitations. The previous lifelong prophylactic treatment in the form of regular injections also means a reduction in quality of life for most patients.
The new gene therapy for hemophilia B patients offers the opportunity to address this unmet need by potentially freeing patients from the burden of frequent infusions and bleeding events in the longer term.

About the Pivotal HOPE-B Trial
The pivotal Phase III HOPE-B trial is an ongoing, multinational, open-label, single-arm study to evaluate the safety and efficacy of HEMGENIX®. Fifty-four adult hemophilia B patients classified as having moderately severe to severe hemophilia B and requiring prophylactic factor IX replacement therapy were enrolled in a prospective, six-month or longer observational period during which time they continued to use their current standard of care therapy to establish a baseline Annual Bleeding Rate (ABR). After the six-month lead-in period, patients received a single intravenous administration of HEMGENIX® at the 2x10^13 gc/kg dose. Patients were not excluded from the trial based on pre-existing neutralizing antibodies (NAbs) to AAV5.
A total of 54 patients received a single dose of HEMGENIX® in the pivotal trial, with 53 patients completing at least 18 months of follow-up. The primary endpoint in the pivotal HOPE-B study was ABR 52 weeks after achievement of stable factor IX expression (months 7 to 18) compared with the six-month lead-in period. For this endpoint, ABR was measured from month seven to month 18 after infusion, ensuring the observation period represented a steady-state factor IX transgene expression. Secondary endpoints included assessment of factor IX activity.
The efficacy results 18 months after treatment with HEMGENIX® demonstrated superiority over the previous continuous routine Factor IX prophylaxis. The annual overall bleeding rate decreased significantly by 64% and 96% of all patients no longer required routine Factor IX prophylaxis. No serious adverse reactions were reported. No inhibitors to factor IX were reported.
Long-term 36-month data presented at the 65th American Society of Hematology (ASH) 2023 Annual Meeting and Exposition continue to reinforce the potential long-lasting efficacy and
safety of HEMGENIX® and the ongoing benefit of this treatment for people living with hemophilia B.

About CSL
CSL (ASX:CSL; USOTC:CSLLY) is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat hemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest.
For more information about CSL, visit

# # #

Media Contacts:

Maria Tortoreto
Mobile: +1 201-248-5208

Célia Rohrer
Mobile: +41 79 599 35 46